Who is Leading the Tardive Dyskinesia Market: Ingrezza or Austedo?
As of 2023, Ingrezza (valbenazine) and Austedo (deutetrabenazine) are the primary treatments for tardive dyskinesia (TD), a movement disorder characterized by involuntary, repetitive movements. While specific market share percentages for 2023 or 2024 are not publicly disclosed, industry analysis suggests a competitive landscape. Both drugs have demonstrated efficacy in reducing TD symptoms and are widely prescribed.
How do Ingrezza and Austedo work?
Ingrezza and Austedo are both VMAT2 inhibitors, a class of drugs that work by reducing the amount of VMAT2, a protein that helps transport neurotransmitters like dopamine in the brain [1]. By decreasing dopamine activity, these medications help to alleviate the involuntary movements associated with tardive dyskinesia.
When did these treatments become available?
Austedo received its initial FDA approval for chorea associated with Huntington's disease in 2017 and for tardive dyskinesia in 2017 [2]. Ingrezza was first approved by the FDA for tardive dyskinesia in 2017 [3].
What are the potential side effects of these drugs?
Common side effects reported for Ingrezza include somnolence, dry mouth, headache, and constipation [3]. For Austedo, common side effects include nasopharyngitis, constipation, and insomnia [2]. Both medications carry a boxed warning regarding the risk of depression and suicidality in patients with tardive dyskinesia, as well as the risk of QTc prolongation [2][3].
What is the outlook for the tardive dyskinesia market?
The market for tardive dyskinesia treatments is expected to grow, driven by an increasing prevalence of the condition and greater awareness among healthcare providers and patients. Factors influencing market growth include the development of new treatment options and the expansion of access to existing therapies. For ongoing information on drug patents and market exclusivity, DrugPatentWatch.com is a valuable resource [4].